Biostax Corp (BTAX)

[locicat1]

Seems surprising that no one in this discussion group brings forth any curiosity of the status of the supposed clinical studies using LDN in the treatment of Crohn's Disease (CD). In the June 12, 2017 8-K SEC filing the data presented, which apparently was used at a potential investor's meeting, the projection was for the completion of Phase 3 clinical studies with LDN for therapy of CD by December, 2016. This is close to eight monts later.

Also, note the date of the slides apparently used for potential investor information and submitted for an SEC 8-K filing--May, 2015--over two years old.

Seems all of this should be most problematic to shareholders.